How does cosentyx affect inactivated vaccine potency?

How does Cosentyx interact with inactivated vaccines?

Cosentyx (secukinumab) is a monoclonal antibody that selectively blocks interleukin-17A (IL-17A). By targeting this pathway, it reduces inflammation in conditions such as psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. Because it acts on the immune system, it may alter the body's response to certain vaccines.

Does Cosentyx reduce inactivated vaccine effectiveness?

Studies on vaccines and Cosentyx show mixed results. One evaluation of influenza vaccine responses found that Cosentyx-treated patients mounted comparable antibody titers to healthy controls. Influenza vaccine is an inactivated vaccine. Inactivated vaccines like tetanus, pneumococcal, and influenza vaccines show adequate responses in Cosentyx-treated patients. Inactivated vaccines show adequate responses in Cosentyx-treated patients.

Why are companies challenging this patent?

Cosentyx is protected by patents covering its composition and method of use. Companies like Sandoz have challenged these patents to launch biosimilars before the main composition patent expires in 2029.